News

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.
Novo Nordisk: Q2 Earnings Snapshot
Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $4.03 billion. On a per-share basis, the Bagsvaerd, Denmark-based company said it had profit of 91 cents. Earnings, adjusted for one-time gains and costs,
Health Care Down on Novo Nordisk Earnings -- Health Care Roundup
Shares of Novo Nordisk continued their slide despite reporting a larger-than-anticipated increase in sales of its Wegovy weight-control drug, as fears of copycat competition remained. The Danish company warned it was still concerned Moderna shares fell after the Department of Health and Human Services said it was winding down its mRNA vaccine-development activities under the Biomedical Advanced Research and Development Authority.
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings of 65 cents per ADR in the year-ago quarter.
Wegovy maker Novo Nordisk sales rise 18% in second quarter
COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock.
Novo Nordisk to Disclose Full Second-Quarter Earnings Amid Management Reshuffle -- Earnings Preview
Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week,
Novo Nordisk Stock Is Dropping After Earnings. It Got Worse.
The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.
Why Novo Nordisk Stock Slipped Today
Novo Nordisk (NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value fol
Zacks.com on MSN22h
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
sharewise3d
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...
AOL29d
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly - AOL
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still ...
sharewise10d
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
Tempus AI TEM and NVIDIA NVDA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing ...
Nasdaq29d
The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo ... - Nasdaq
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-50.5% vs. -15.9%). The company’s failure to meet the weight-loss target with ...